Berma Research Group-Atlanta LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$3,360	1
2023	Research	$26,645	2
2022	Research	$50,568	2
2021	Research	$30,597	2
2020	Research	$37,339	2
2019	Research	$3,000	1

Breakdown

Who paid Research payments · program years 2019–2024

Otsuka Pharmaceutical Development & Commercialization, Inc. $151,508 10 payments

Studies the money was for Research payments · program years 2019–2024

A Multicenter, Randomized, Double-Blind, Placebo-And Active-Controlledtrial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia $82,234 5 payments
A Long-Term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole As Maintenance Treatment in Adolescent Patients With Schizophrenia $66,275 4 payments
A Multicenter, Randomized, Double-Blind, Placebo-And Active-Controlledtrial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents 13-17 Years Old With Schizophrenia $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.